{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous&page=23", "query": { "condition": "Cutaneous", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1580, "total_pages": 158, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T23:19:46.949Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02110355", "title": "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Advanced Solid Tumors", "Cancer", "Oncology", "Oncology Patients", "Tumors", "Melanoma" ], "interventions": [ { "name": "AMG 232", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-12-19", "completion_date": "2018-12-27", "has_results": false, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02110355" }, { "nct_id": "NCT01843998", "title": "Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T-cell Lymphoma (CTCL)" ], "interventions": [ { "name": "Sirolimus 0.1% Ointment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stefan Schieke MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-02", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2015-06-04", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843998" }, { "nct_id": "NCT01535963", "title": "Patient Satisfaction in Cutaneous Surgery", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Skin Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 354, "start_date": "2012-06", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01535963" }, { "nct_id": "NCT07406893", "title": "Reduction of Bacterial Seeding in Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Joint Arthroplasty", "Shoulder", "Cutibacterium Acnes", "Prosthetic Joint Infection" ], "interventions": [ { "name": "Prontosan Wound Gel", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "St. Louis University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-02-23", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07406893" }, { "nct_id": "NCT06827548", "title": "Recording Cutaneous Vagal Nerve Activity With Multi-Electrode Array (MEA) in Patients Undergoing VNS Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vagus Nerve Stimulation" ], "interventions": [ { "name": "Multi-Electrode Array (MEA) Recording", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2021-05-26", "completion_date": "2022-07-13", "has_results": true, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06827548" }, { "nct_id": "NCT03011814", "title": "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Folliculotropic Mycosis Fungoides", "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Sezary Syndrome", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2017-03-08", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 4, "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03011814" }, { "nct_id": "NCT01755247", "title": "A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Topical Gel Vehicle", "type": "DRUG" }, { "name": "8% NVN1000 Topical Gel", "type": "DRUG" }, { "name": "8% NVN1000 Topical Gel and moisturizer", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novan, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2012-11", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 1, "location_summary": "Broomall, Pennsylvania", "locations": [ { "city": "Broomall", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01755247" }, { "nct_id": "NCT06984328", "title": "Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)", "Metastatic Cutaneous Melanoma (Stage IV)" ], "interventions": [ { "name": "Acasunlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2025-07-25", "completion_date": "2026-05-15", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06984328" }, { "nct_id": "NCT01134341", "title": "Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-cell Lymphoma", "Mycosis Fungoides", "Sezary Syndrome", "Primary Cutaneous Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Pralatrexate Injection", "type": "DRUG" }, { "name": "Bexarotene Capsules", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2010-03", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 4, "location_summary": "Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01134341" }, { "nct_id": "NCT01708941", "title": "Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2013-03-25", "completion_date": "2026-05-26", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-10T23:19:46.949Z", "location_count": 276, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 184 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708941" } ] }